reports
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Model update, multiple important catalysts ahead
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
Zealand Pharma to present at the J.P. Morgan Healthcare Conference Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take part in a presenta...
Total number of shares and voting rights in Zealand Pharma as of Decem...
Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which change...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...
- Jacob Mekhael
Zealand Pharma CMD key takeaways
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Mathijs Geerts Danau
Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Zealand Pharma and OTR Therapeutics enter multi-program strategic coll...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received i...
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET)Venue: Goldman...
- Mathijs Geerts Danau
Zealand Pharma Uneventful 3Q25 results, upcoming CMD in December 2025
Zealand reported 3Q25 results and provides a business update which are in line with expectations. We note that dapiglutide development has been paused but that most important timelines have been reiterated. For the remainder or this year we do not expect big readouts, but look forward to the CMD in December. DKK 1,120 TP and BUY rating reiterated.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma Announces Financial Results for the First Nine Months o...
Zealand Pharma Announces Financial Results for the First Nine Months of 2025 Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline...
Zealand Pharma to participate in the Jefferies Global Healthcare Confe...
Zealand Pharma to participate in the Jefferies Global Healthcare Conference Press release – No. 16 / 2025 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 10:30am GMT (11:30am CET) on Wednesday, November 19, 2025. A ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.